HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HOLDER, A. T. Articles by PREECE, M. A. Search for Related Content PubMed Articles by HOLDER, A. T. Articles by PREECE, M. A.

The growth-promoting effects of a partially purified preparation of somatomedin (12·7 units/mg) were compared with those of various doses of bovine GH (5, 20 and 80 µg/day) when injected into hypopituitary dwarf mice. Growth parameters studied were body-weight and tail-length velocities (calculated as the slope of a regression line fitted to daily measurements against time), uptake of ³⁵SO^2–₄ into costal cartilage in vivo and organ weights (heart, liver and kidney). In the first experiment somatomedin (6·4 units/day), bovine GH and 0·9% NaCl were injected once daily in a volume of 0·1 ml for 10 days. Treatment with bovine GH promoted a significant dose-dependent increase in body-weight and tail-length velocities and ³⁵SO^2–₄ uptake into costal cartilage in vivo. Somatomedin also promoted a significant increase in body-weight velocity and ³⁵SO^2–₄ uptake, both responses were between that observed with the lowest dose of bovine GH and control values. Somatomedin did not promote increase in tail-length velocity. Organ weights did not differ significantly between any of the treatment groups when expressed as mg/g body weight. In the second experiment somatomedin (a daily total of 21·6 units/day) and 0·9% NaCl were injected three times per day in a volume of 0·033 ml, bovine GH was again injected once daily in a volume of 0·1 ml, and the treatment period was 12 days. As in the first experiment all doses of bovine GH and somatomedin promoted a significant increase in body-weight velocity. These results are consistent with the somatomedin hypothesis.

This article has been cited by other articles:

				V. Wallenius, K. Wallenius, M. Hisaoka, J. Sandstedt, C. Ohlsson, M. Kopf, and J.-O. Jansson Retarded Liver Growth in Interleukin-6-Deficient and Tumor Necrosis Factor Receptor-1-Deficient Mice Endocrinology, July 1, 2001; 142(7): 2953 - 2960. [Abstract] [Full Text] [PDF]

				J.-L. Liu, S. Yakar, and D. LeRoith Conditional Knockout of Mouse Insulin-Like Growth Factor-1 Gene Using the Cre/loxP System Experimental Biology and Medicine, April 1, 2000; 223(4): 344 - 351. [Abstract] [Full Text] [PDF]

				K. Sjogren, J.-L. Liu, K. Blad, S. Skrtic, O. Vidal, V. Wallenius, D. LeRoith, J. Tornell, O. G. P. Isaksson, J.-O. Jansson, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice PNAS, June 8, 1999; 96(12): 7088 - 7092. [Abstract] [Full Text] [PDF]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]

				O. Isaksson, J. Jansson, and I. Gause Growth hormone stimulates longitudinal bone growth directly Science, June 11, 1982; 216(4551): 1237 - 1239. [Abstract] [PDF]